Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Office of Regulatory Affairs Makeover Blends Domestic, International Work

This article was originally published in The Tan Sheet

Executive Summary

The reorganized ORA has eight new offices to better handle new legislative authorities and globalization of its regulated products; FDA expects to increase partnerships with other government officials and foreign entities.

You may also be interested in...



People In Brief: Soller consults, Sharaf joins AHPA, Perrigo hires Crabill, Villaraigosa advises Herbalife

Soller leaves UCSF to consult full-time; Aker hires former Clavis Pharma scientists for krill R&D; Perrigo adds nutritional regulatory manager; USP veteran Sharaf joins AHPA; ex-mayor of Los Angeles advises Herbalife; FDA’s Plaisier earns permanent ORA appointment; more People In Brief.

People In Brief: Soller consults, Sharaf joins AHPA, Perrigo hires Crabill, Villaraigosa advises Herbalife

Soller leaves UCSF to consult full-time; Aker hires former Clavis Pharma scientists for krill R&D; Perrigo adds nutritional regulatory manager; USP veteran Sharaf joins AHPA; ex-mayor of Los Angeles advises Herbalife; FDA’s Plaisier earns permanent ORA appointment; more People In Brief.

FDA Drug Shortage Staff Gets Higher Profile As New Reporting Requirements Begin

The 11-member staff CDER devotes to drug shortages is moving to the Office of the Center Director and will report to Deputy Director for Regulatory Programs Doug Throckmorton.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel